Zeposia

Multiple Sclerosis

Zeposia is used to treat adults with relapsing forms of multiple sclerosis (MS). This includes the following conditions:

• Clinically isolated syndrome (CIS): This is often the first episode of MS symptoms.
• Relapsing-remitting disease (RRMS): This is the most common form of MS, characterized by clear attacks followed by periods of recovery.
• Active secondary progressive disease (SPMS): This is a stage of MS where the disease progresses more steadily, but relapses still occur.

The medication is used to help decrease the frequency of MS relapses and may help slow the accumulation of physical disability caused by the disease.

Ulcerative Colitis

Zeposia is also approved for the treatment of adults with moderately to severely active ulcerative colitis. Ulcerative colitis is an inflammatory bowel disease that causes swelling and sores in the digestive tract. Zeposia is used to help reduce inflammation, manage symptoms, and achieve or maintain clinical remission.

Mechanism of Action

Zeposia belongs to a class of medications called sphingosine 1-phosphate (S1P) receptor modulators. It is used to treat certain types of multiple sclerosis and ulcerative colitis by altering how the immune system behaves.

How it Affects Immune Cells

In autoimmune conditions, the body's immune system mistakenly attacks healthy tissues. White blood cells known as lymphocytes are often responsible for this damage. Zeposia works by:

• Binding to specific receptors on the surface of lymphocytes.
• Preventing these cells from exiting the lymph nodes and entering the bloodstream.
• Reducing the total number of active immune cells that can travel to the brain, spinal cord, or the lining of the large intestine.

By keeping these cells sequestered in the lymph nodes, Zeposia helps lower inflammation and prevents the immune system from attacking the protective coating of nerves or the digestive tract.

Common Side Effects

Many people using Zeposia experience mild side effects. These may include:

• Upper respiratory tract infections, such as the common cold or sinus pressure.
• Back pain.
• Headache.
• Dizziness.
• Changes in blood pressure.
• Painful or frequent urination.
• Increased levels of liver enzymes.

Serious Side Effects

While less common, Zeposia can cause serious health problems. Contact a healthcare provider immediately if you experience:

• Heart rhythm changes: A slow heart rate, especially after the first dose, which may cause dizziness or lightheadedness.
• Infections: Increased risk of serious viral, bacterial, or fungal infections.
• Liver injury: Symptoms such as nausea, vomiting, stomach pain, fatigue, dark urine, or yellowing of the skin and eyes.
• Vision problems: Blurred vision or a blind spot in the center of your vision (macular edema).
• Breathing issues: New or worsening shortness of breath.
• Neurological symptoms: Sudden severe headache, confusion, seizures, or vision loss, which could indicate a rare condition called posterior reversible encephalopathy syndrome (PRES).
• Severe blood pressure increase: A significant rise in blood pressure that requires medical attention.

If you stop taking Zeposia, your symptoms may become significantly worse than they were before or during treatment. Do not stop the medication without consulting your doctor.

Heart and Rhythm Concerns

Zeposia should not be used by individuals who have experienced certain heart problems within the last six months, including heart attack, unstable angina, stroke, or certain types of heart failure. It is also contraindicated for people with specific heart rhythm disorders, such as sick sinus syndrome or second- or third-degree atrioventricular (AV) block, unless a functional pacemaker is in place.

The medication can cause a temporary decrease in heart rate when first started. Healthcare providers typically perform an electrocardiogram (ECG) to check heart rhythm before the first dose.

Infections and Immune System

Because Zeposia affects the immune system, it can increase the risk of serious or life-threatening infections. Treatment should not begin if an active infection is present. Healthcare providers usually test for tuberculosis and chickenpox (varicella zoster) immunity before starting the drug. There is also a rare risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection.

Liver and Blood Pressure

This medication may cause liver injury. Blood tests to monitor liver enzymes are typically required before and during treatment. Additionally, Zeposia can cause an increase in blood pressure, which should be monitored regularly.

Vision and Lung Function

Some individuals may develop macular edema, which is swelling in the back of the eye. This risk is higher for those with a history of diabetes or uveitis. Zeposia may also cause a slight decrease in lung function, and breathing tests may be performed if symptoms develop.

Pregnancy and Other Precautions

• Pregnancy: Zeposia may harm an unborn baby. Effective contraception should be used during treatment and for three months after the last dose.
• MAO Inhibitors: This medication should not be taken with monoamine oxidase (MAO) inhibitors, as this can cause dangerously high blood pressure.
• Vaccinations: Certain live vaccines should be avoided during treatment and for three months after stopping.
• Posterior Reversible Encephalopathy Syndrome (PRES): This is a rare but serious brain syndrome that has been reported with this class of drugs. Symptoms include sudden severe headache, confusion, or vision loss.

Pregnancy

Zeposia may cause harm to a developing fetus. Animal studies have shown that the medication can lead to birth defects and other developmental issues. Because of these risks, healthcare providers typically recommend avoiding Zeposia during pregnancy.

If you are able to become pregnant, you should use effective birth control while taking Zeposia and for at least three months after your last dose. This is because the medication can stay in your system for several months after you stop taking it. If you become pregnant while taking this medication, you should contact your doctor immediately to discuss the potential risks.

Breastfeeding

It is currently unknown whether Zeposia passes into human breast milk or if it could affect a nursing infant. Because the potential risks to a baby are not fully understood, it is important to talk with your healthcare provider about the best way to feed your baby while taking this medication.

Zeposia is provided as capsules for oral administration. The medication is available in multiple strengths to support a gradual increase in dosage when treatment first begins.

Titration Starter Pack

A starter pack is used for the first seven days of treatment. This packaging contains capsules of different strengths to allow for a step-wise increase in the dose, which helps the body adjust to the medication. The pack is organized into:

• Lower-strength capsules for the first four days of treatment.
• Intermediate-strength capsules for days five through seven.

Maintenance Capsules

Following the completion of the starter pack, Zeposia is taken as a single maintenance strength capsule once daily.

FDA Approval and Indications

Zeposia was first approved by the U.S. Food and Drug Administration (FDA) in March 2020. It is classified as a sphingosine 1-phosphate (S1P) receptor modulator.

The medication is currently approved for the following conditions in adults:

• Relapsing forms of multiple sclerosis (MS): This includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
• Ulcerative colitis: It is approved for the treatment of moderately to severely active ulcerative colitis.

Regulatory Requirements and Safety Monitoring

While Zeposia does not carry a boxed warning, the FDA requires specific medical evaluations before a patient starts treatment. Healthcare providers must perform a baseline electrocardiogram (ECG) to check for heart rhythm issues, conduct liver function tests, and verify a complete blood count. Patients must also be screened for certain infections, such as the varicella-zoster virus, and may require an ophthalmic evaluation if they have a history of uveitis or macular edema.

There are currently no active Risk Evaluation and Mitigation Strategy (REMS) programs or major safety recalls reported for this medication in the provided documentation.

Factors Affecting Cost

The actual price you pay for Zeposia can vary based on several factors. Because it is a specialty medication, it is often not available at standard retail pharmacies and must be dispensed through a specialty pharmacy. Key factors include:

• Insurance Coverage: Your specific health insurance plan, including your deductible, copayment, or coinsurance requirements, will determine your out-of-pocket costs.
• Treatment Phase: Costs may vary between the initial starter pack used for dose titration and the ongoing maintenance doses.
• Pharmacy Selection: Different specialty pharmacies may have different pricing structures or contracts with insurance providers.

Financial Assistance Programs

Since Zeposia is a high-cost medication, there are often programs available to help manage the expense:

• Copay Savings Cards: Patients with commercial or private insurance may be eligible for manufacturer-sponsored copay cards that significantly reduce monthly costs.
• Patient Assistance Programs: For individuals without insurance or those who are underinsured, non-profit organizations or the drug manufacturer may provide the medication at a reduced cost or for free based on financial need.
• Support Services: The manufacturer often provides a support program to help patients navigate insurance approvals and identify financial resources.

Generic Availability

There is currently no generic version of Zeposia (ozanimod) available. Generic drugs typically cost less than brand-name medications, but brand-name drugs remain the only option until patent protections expire and the FDA approves a generic alternative.